Australia based biotech company focused on oncology, Kazia Threapeutics Limited (ASX:KZA), on 18 November 2020, in an ASX announcement, shared a summary of new paxalisib data submitted at the annual meeting of Society for Neuro-Oncology (SNO), to be held virtually from 19-21 November 2020.
Key pointers feature:
- The latest interim study of paxalisib phase 2 study in glioblastoma is very much consistent with the previous data.
- The analysis suggested median progression-free survival of 8.4 months.
- Median overall survival of 17.5 months reported.
- First significant presentation of safety data at a 60mg dose showcases profile similar to the previous experience. Most common toxicities include rash, stomatitis and hyperglycemia.
Kazia CEO Dr James Garner shared that this is quite reassuring data from the glioblastoma study. This confirms that the earlier results with the data are now much more mature.
Meanwhile, the KZA stock soared up by 34.453% at $1.600 with a market capitalisation of $150.13 million at 2:14 PM AEDT.
